Vishal A. Patel, MD, FAAD, FACMS, GW Cancer Center

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.

A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.